Mach7 Technologies AI Stock Analysis
Mach7 Technologies (TDMMF) AI Stock Analysis
Mach7 Technologies
(Other OTC:TDMMF)
No summary available
Mach7 Technologies (TDMMF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $49.19M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,812
- Price to Earnings (P/E)
- -7.1
- Beta (1Y)
- 0.41
- Revenue Growth
- -13.39%
- EPS Growth
- -53.61%
- Country
- US
- Employees
- 167
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Mach7 Technologies Business Overview & Revenue Model
Company Description
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise d...
Mach7 Technologies Earnings Call Summary
The call presented a cautious but constructive tone: FY'26 was framed as a deliberate reset that materially improved the business foundation—higher-quality recurring revenue mix, a 93% gross margin, reduced operating costs, a stronger leadership team, and clear second-half commercial momentum (ARR run rate +7.6% constant currency; H2 revenue +15% vs H1). However, meaningful near-term challenges remain including a 17% reported revenue decline, several sizable customer losses (notably VHA and Trinity Health), an $8.9M net loss, and FX-driven reporting headwinds. Management emphasized stabilization and a roadmap (Flamingo modules, Epic integrations, focused partnerships) to prove growth in FY'27. Overall, positives around margin, cash/no debt, cost discipline and H2 recovery modestly outweigh the lowlights, supporting cautious optimism.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management set four clear FY‑27 priorities—ARR growth, new customer wins, Flamingo adoption and OpEx discipline—and gave FY‑26 baselines to measure progress: FY‑26 total revenue $27.9M (recurring $23.4M), CAR $25.5M and an ARR run‑rate of $23.5M; revenue was down 17% YoY (recurring down 8%), capital license revenue $1.5M (‑17%), while ARR run‑rate was up 7.6% on a constant‑currency basis and CAR was down 9% constant currency. They closed FY‑26 with operating expenses $26.7M (down $5.1M or 16%), gross margin 93%, adjusted EBITDA loss of $0.9M, net loss before amortization $2.9M, net loss after tax $8.9M, cash $19.9M and no debt; cash receipts were $28M and operating cash flow was negative for the year but positive in 3 of 4 quarters (Q1 ‑$3.7M, Q2 ~breakeven, Q3 +$1.2M, Q4 +$1.1M). Second‑half momentum (constant‑currency revenue H2 $15.6M vs H1 $13.5M, +15%), stronger bookings (TCV up 80% H2 vs H1; 86% ARR‑type; 40% of orders in Q4; 21% new logos) and one‑offs (restructuring $1.9M, deferred tax write‑off ≈$1M) provide the starting point for proving recurring revenue growth, module adoption and operating leverage in FY‑27.
Mach7 Technologies Peers Comparison
Overall Rating
AU:PME76Outperform
AU:ALC69Neutral
AU:ONE48Neutral
AU:AYA46Neutral
AU:BMT45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | AUD 21.07B | 79.39 | 63.19% | 0.34% | 22.87% | 130.30% | |
| 69Neutral | AUD 168.73M | 70.59 | 2.53% | ― | 26.61% | 38.21% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | AUD 100.70M | -5.74 | -203.69% | ― | -1.53% | 28.29% | |
| 46Neutral | AUD 476.83M | -16.67 | -30.04% | ― | <0.01% | 2.08% | |
| 45Neutral | AUD 19.79M | -1.06 | -58.13% | ― | 2.08% | -195.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TDMMF | Mach7 Technologies Ltd. | 0.21 | -0.29 | -58.20% | |
| AU:ONE | Oneview Healthcare PLC Chess Depository Interests repr 1 | 0.12 | -0.17 | -58.62% | |
| AU:PME | Pro Medicus Limited | 201.65 | -50.16 | -19.92% | |
| AU:BMT | Beamtree Holdings Ltd | 0.07 | -0.13 | -66.50% | |
| AU:AYA | Artrya Limited | 2.90 | -0.27 | -8.52% | |
| AU:ALC | Alcidion Group Limited | 1.25 | 0.25 | 25.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
